All Posts

Emicizumab in VWD

The opening plenary session of the World Federation of Hemophilia featured von Willebrand disease expert Dr. Peter Lenting, who reported on “Novel Treatment Options in von Willebrand Disease.” He reported on a case study in which emicizumab was used to successfully treat a type 3 VWD patient with anti-VWF inhibitors. The case study presentation appears […]

Bleeding Disorders

ISTH Guidelines for Treatment of TTP

Reminder, in 2020, the International Society for Thrombosis and Hemostasis [ISTH} released their “ISTH Diagnosis Guidelines” and “ISTH TTP Treatment Guidelines.”Click here for access to the guidelines and their supporting material.”

Bleeding Disorders

Chromogenic Factor IX Assay

On May 9, 2022, Precision BioLogic, Inc. [PBI] announced the release and international approval for their chromogenic factor IX assay. Click here for PBI’s press release. The product addresses the key need for accuracy when monitoring extended half-life coagulation factor concentrate therapy.

Bleeding Disorders

ASCLS Annual Meeting June 26–30

The ASCLS, AGT, and SAFMLS hybrid annual meeting [JAM] is planned for June 26–30, 2022 in Grand Rapids, MI. Click here for the details. George presents Operating Room Hemostasis Testing Wednesday, June 29, in-person 1:45–2:45 ET. The talk includes how the OR employs the activated clotting time or viscoelastometry to monitor heparin superdosing and reversal. […]

May 2022 Cheat Sheet

Click here for our May 2022 Cheat Sheet.

May 2022 QQ: Thrombosis Risk Profile

Our May 2022 Quick Question asks, “What assay should be deleted from the thrombosis risk factor profile?” Thrombosis risk testing has been available to us since von Kaulla first described “antithrombin 3” deficiency in 1972 using the “serum antithrombin” test. It gained momentum when Dahlbach described activated protein C resistance in 1994, and thrombosis risk […]

Quick Question Archive

April 2022 QQ: Measuring Heparin Summary

Hello, our April 2022 Quick Question asks, “How do you measure unfractionated heparin [UFH]?” Our 37 respondents answered… Chromogenic anti-Xa using a hybrid curve: 38% [14] Chromogenic anti-Xa using the UFH curve: 14% [5] Anti-Xa and PTT: 22% [8] PTT: 26% [9] The majority of respondents are using the chromogenic anti-Xa heparin assay, and most […]

Anticoagulant Therapy

Clumsy Clinical Communication: ASCLS-DC, DEL, MAR, VA

George provides a virtual presentation, “Clumsy Clinical Communication, Let’s Blame the Lab” on Saturday, April 23, 2–3 EDT, sponsored by the American Society for Clinical Laboratory Science Capital-area associations. Click here to register and link; ASCLS-DE, ASCLS-MD, ASCLS-VA, and ASCLS-CAS(DC). Here are the handouts for George’s presentation in one-per-page form for those who prefer to […]

Laboratory Professionals Week

We belatedly acknowledge the Canadian Society for Medical Laboratory Science/Societe Canadienne de Science de Laboratoire Medical National Medical Laboratory Week, which just ended, 10–16 April, and announce the upcoming Medical Laboratory Professionals Week, April 24–30.

ASCLS-IN 4-9-22 Presentation Handouts

On Saturday, April 9, 2022, 9:15 AM CT, George presents “Clumsy Clinical Communication, Let’s Blame the Lab” for the ASCLS ASCLS-IN / ASCLS-KY 2022 Collaborative Laboratory Conference in Vincennes, Indiana. We’ve attached the presentation handouts in one-per-page form for those who wish to follow on their tablet and six-per-page for those who prefer to print. […]

Load more

George Fritsma is a medical laboratory scientist, educator, and author. George is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

Cheat Sheets from George

Quick Question